Buy-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
1
Favorite

EquityKing
2021-04-23

Buy

Why Ocugen Shares Skyrocketed Today

Ocugen Inc OCGN 42.92% shares soared 42.9% in the regular session and another 11% in the after-hours

Why Ocugen Shares Skyrocketed Today

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment（1）

Top
Latest

EquityKing
·2021-04-23
[Miser]
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":376791650,"tweetId":"376791650","gmtCreate":1619146781070,"gmtModify":1704720365357,"author":{"id":3568290085916641,"idStr":"3568290085916641","authorId":3568290085916641,"authorIdStr":"3568290085916641","name":"EquityKing","avatar":"https://static.tigerbbs.com/6cddc9965d334dafd119ae3d57fb077d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.29","exceedPercentage":"93.85%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Buy</p></body></html>","htmlText":"<html><head></head><body><p>Buy</p></body></html>","text":"Buy","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/376791650","repostId":1137961906,"repostType":4,"repost":{"id":"1137961906","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1619145390,"share":"https://www.laohu8.com/m/news/1137961906?lang=&edition=full","pubTime":"2021-04-23 10:36","market":"us","language":"en","title":"Why Ocugen Shares Skyrocketed Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1137961906","media":"Benzinga","summary":"Ocugen Inc OCGN 42.92% shares soared 42.9% in the regular session and another 11% in the after-hours","content":"<p><b>Ocugen Inc</b>&nbsp;OCGN 42.92%&nbsp;shares soared 42.9% in the regular session and another 11% in the after-hours session on Thursday.</p><p><img src=\"https://static.tigerbbs.com/a5596cd8cf4db1a7bb5b759d4f269eeb\" tg-width=\"1022\" tg-height=\"459\"></p><p><b>What Happened:</b>&nbsp;The shares surged following positive clinical data announced by a partner of Ocugen and a bullish stance taken by Roth Capital analyst Zegbeh Jallah who has a Buy rating on the stock and a 12-month price target of $10.</p><p>Earlier, on Wednesday, Ocugen’s co-development partner Bharat Biotech said that the second interim analysis of Phase 3 of Covaxin, a COVID-19 vaccine candidate, shows itdemonstrated 78% efficiencyin mild, moderate, and severe disease.</p><p>The vaccine is reportedly 100% effective against severe forms of viral illness.</p><p>In a note, Jallah said that Ocugen has sufficient information to support the filing of an Emergency Use Authorization application in the United States.</p><p>“If granted, this could lead to a significant revenue generating opportunity for Ocugen,” wrote the analyst.</p><p>Jallah said that management has confirmed plans to make Covaxin available in the U.S.</p><p>The vaccine’s initial batches will undergo test and release at a U.S. facility approved by the Food and Drug Administration, as per Jallah.</p><p>Meanwhile, Bharat Biotech isramping up manufacturingto produce 700 million COVID-19 vaccine doses annually.</p><p>Earlier in the month, it was reported that Ocugen plans to sell100 million Covaxin dosesin the U.S.</p><p><b>Price Action:</b>&nbsp;Ocugen shares closed 42.92% higher at $9.29 on Thursday and rose another almost 11% to $10.31 in the after-hours trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Ocugen Shares Skyrocketed Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Ocugen Shares Skyrocketed Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-23 10:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Ocugen Inc</b>&nbsp;OCGN 42.92%&nbsp;shares soared 42.9% in the regular session and another 11% in the after-hours session on Thursday.</p><p><img src=\"https://static.tigerbbs.com/a5596cd8cf4db1a7bb5b759d4f269eeb\" tg-width=\"1022\" tg-height=\"459\"></p><p><b>What Happened:</b>&nbsp;The shares surged following positive clinical data announced by a partner of Ocugen and a bullish stance taken by Roth Capital analyst Zegbeh Jallah who has a Buy rating on the stock and a 12-month price target of $10.</p><p>Earlier, on Wednesday, Ocugen’s co-development partner Bharat Biotech said that the second interim analysis of Phase 3 of Covaxin, a COVID-19 vaccine candidate, shows itdemonstrated 78% efficiencyin mild, moderate, and severe disease.</p><p>The vaccine is reportedly 100% effective against severe forms of viral illness.</p><p>In a note, Jallah said that Ocugen has sufficient information to support the filing of an Emergency Use Authorization application in the United States.</p><p>“If granted, this could lead to a significant revenue generating opportunity for Ocugen,” wrote the analyst.</p><p>Jallah said that management has confirmed plans to make Covaxin available in the U.S.</p><p>The vaccine’s initial batches will undergo test and release at a U.S. facility approved by the Food and Drug Administration, as per Jallah.</p><p>Meanwhile, Bharat Biotech isramping up manufacturingto produce 700 million COVID-19 vaccine doses annually.</p><p>Earlier in the month, it was reported that Ocugen plans to sell100 million Covaxin dosesin the U.S.</p><p><b>Price Action:</b>&nbsp;Ocugen shares closed 42.92% higher at $9.29 on Thursday and rose another almost 11% to $10.31 in the after-hours trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137961906","content_text":"Ocugen Inc OCGN 42.92% shares soared 42.9% in the regular session and another 11% in the after-hours session on Thursday.What Happened: The shares surged following positive clinical data announced by a partner of Ocugen and a bullish stance taken by Roth Capital analyst Zegbeh Jallah who has a Buy rating on the stock and a 12-month price target of $10.Earlier, on Wednesday, Ocugen’s co-development partner Bharat Biotech said that the second interim analysis of Phase 3 of Covaxin, a COVID-19 vaccine candidate, shows itdemonstrated 78% efficiencyin mild, moderate, and severe disease.The vaccine is reportedly 100% effective against severe forms of viral illness.In a note, Jallah said that Ocugen has sufficient information to support the filing of an Emergency Use Authorization application in the United States.“If granted, this could lead to a significant revenue generating opportunity for Ocugen,” wrote the analyst.Jallah said that management has confirmed plans to make Covaxin available in the U.S.The vaccine’s initial batches will undergo test and release at a U.S. facility approved by the Food and Drug Administration, as per Jallah.Meanwhile, Bharat Biotech isramping up manufacturingto produce 700 million COVID-19 vaccine doses annually.Earlier in the month, it was reported that Ocugen plans to sell100 million Covaxin dosesin the U.S.Price Action: Ocugen shares closed 42.92% higher at $9.29 on Thursday and rose another almost 11% to $10.31 in the after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":543,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":4109992,"commentId":"4109992","gmtCreate":1619146793160,"gmtModify":1680785224641,"authorId":3568290085916641,"author":{"id":3568290085916641,"idStr":"3568290085916641","authorId":3568290085916641,"name":"EquityKing","avatar":"https://static.tigerbbs.com/6cddc9965d334dafd119ae3d57fb077d","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.29","exceedPercentage":"93.85%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":376791650,"objectIdStr":"376791650","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"[Miser]","text":"[Miser]","html":"[Miser]","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}